BG105127A - Method for treament of nicotine addiction - Google Patents

Method for treament of nicotine addiction

Info

Publication number
BG105127A
BG105127A BG105127A BG10512701A BG105127A BG 105127 A BG105127 A BG 105127A BG 105127 A BG105127 A BG 105127A BG 10512701 A BG10512701 A BG 10512701A BG 105127 A BG105127 A BG 105127A
Authority
BG
Bulgaria
Prior art keywords
treament
nicotine addiction
smoking
paroxetine
solvate
Prior art date
Application number
BG105127A
Other languages
Bulgarian (bg)
English (en)
Inventor
Martin Steiner
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG105127A publication Critical patent/BG105127A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG105127A 1998-06-16 2001-01-08 Method for treament of nicotine addiction BG105127A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812941.4A GB9812941D0 (en) 1998-06-16 1998-06-16 Method of treatment
PCT/US1999/013623 WO1999065491A1 (en) 1998-06-16 1999-06-16 Method of treatment

Publications (1)

Publication Number Publication Date
BG105127A true BG105127A (en) 2001-11-30

Family

ID=10833832

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105127A BG105127A (en) 1998-06-16 2001-01-08 Method for treament of nicotine addiction

Country Status (20)

Country Link
EP (1) EP1087766A4 (xx)
JP (1) JP2002518330A (xx)
KR (1) KR20010052895A (xx)
CN (1) CN1305379A (xx)
AP (1) AP2000002002A0 (xx)
AU (1) AU740749B2 (xx)
BG (1) BG105127A (xx)
BR (1) BR9911150A (xx)
CA (1) CA2335236A1 (xx)
CZ (1) CZ20004698A3 (xx)
EA (1) EA003584B1 (xx)
GB (1) GB9812941D0 (xx)
HU (1) HUP0102507A3 (xx)
IL (1) IL139943A0 (xx)
NO (1) NO20006383L (xx)
NZ (1) NZ508532A (xx)
PL (1) PL345261A1 (xx)
SK (1) SK19192000A3 (xx)
WO (1) WO1999065491A1 (xx)
ZA (1) ZA200007396B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303827A2 (hu) * 2000-08-28 2004-04-28 Synthon B.V. Paroxetinkészítmények és eljárások ezek előállítására
EP1465601A4 (en) 2001-12-28 2006-02-15 Teva Pharma STABLE PHARMACEUTICAL FORMULATION OF PAROXETINE ANHYDROUS HYDROCHLORIDE AND PREPARATION METHOD
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
WO1992009281A2 (en) * 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method

Also Published As

Publication number Publication date
HUP0102507A3 (en) 2003-12-29
SK19192000A3 (sk) 2001-05-10
AU4688599A (en) 2000-01-05
ZA200007396B (en) 2002-02-27
EA200100041A1 (ru) 2001-06-25
GB9812941D0 (en) 1998-08-12
CN1305379A (zh) 2001-07-25
CA2335236A1 (en) 1999-12-23
EP1087766A1 (en) 2001-04-04
AP2000002002A0 (en) 2000-12-31
AU740749B2 (en) 2001-11-15
PL345261A1 (en) 2001-12-03
CZ20004698A3 (cs) 2002-02-13
IL139943A0 (en) 2002-02-10
KR20010052895A (ko) 2001-06-25
WO1999065491A1 (en) 1999-12-23
NO20006383D0 (no) 2000-12-14
EA003584B1 (ru) 2003-06-26
BR9911150A (pt) 2001-03-06
NZ508532A (en) 2003-08-29
JP2002518330A (ja) 2002-06-25
NO20006383L (no) 2000-12-14
HUP0102507A2 (hu) 2002-05-29
EP1087766A4 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
BG105459A (en) Pharmaceutical moxifloxacin preparation
WO2000016762A3 (en) Method for reducing nicotine dependency
AUPN603895A0 (en) Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
IL206830A (en) Use of an integrin-containing antagonist of the alpha 1 subunit - of the integrin to prepare a drug for the treatment of osteoporosis
MY127739A (en) Use of pramipexole for the treatment of addictive disorders
RS115204A (xx) Postupak za pomaganje prestanka pušenja
PT998287E (pt) Utilizacao de levobupivacaina
HUP0300048A2 (hu) Transzdermális vagy transzmukozális dohányzásról leszoktató készítmények, melyek nikotintartalmú hatóanyagkombinációt tartalmaznak és alkalmazásuk
ZA200004406B (en) Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
BG105127A (en) Method for treament of nicotine addiction
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
AP2000002017A0 (en) Salts of paroxetine.
AU3393600A (en) Method for safely and effectively administering a drug by inhalation
NO20012226D0 (no) Terapeutiske midler for medikamentavhengighet
WO2002007733A3 (en) Method for enhancing bone mineral density gain by administration of raloxifene
IL126158A0 (en) Method for treating substance abuse
GB9410482D0 (en) Tobacco smokers' mouthpiece
EP1221945A4 (en) METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
HUP0103459A2 (hu) (2S,3S,5R)-2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinol tartalmú, orális adagolási formák hatékony mennyiségű stabilizáló alginsavval
AU9235101A (en) Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof
PL346342A1 (en) The use of r(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
YU59102A (sh) JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR